Table II.

Analysis of the DR11 effect

MenaWomenaAll Patientsa
SPRPSPRPSPRP
All patientsn = 122n = 59n = 41n = 12n = 201n = 76
HLA-DR11 patients28 (22.9%)18 (30.5%)10 (24.3%)9 (75%)41 (20.4%)28 (42.4%)
p value0.280.0040.007
DR4-negative patientsn = 97n = 48n = 30n = 11n = 153n = 61
HLA-DR11 patients16 (16.4%)18 (37.5%)8 (26.6%)9 (81.8%)29 (18.9%)28 (45.9%)
p value0.0070.0030.0001
  • a Gender was not available for all patients.

  • b p values were computed for DR11+ vs DR11 patients in SP vs RP groups.